Deal Final Stages Mein Hai!
Yaar, ye deal 2 saal se chal rahi thi aur ab lagta hai ki finally finalize hone wali hai. Sunne mein aa raha hai ki exclusivity agreement bhi ho gaya hai. Warburg Pincus, Maneesh Pharma ke non-tuberculosis (non-TB) wale medicines ka portfolio ₹1,600 crore se lekar ₹1,800 crore tak mein acquire karne ke liye ready hai.
Maneesh Ke Brands Hain Zabardast!
Maneesh Pharma ke paas kuch bahut hi solid brands hain, jaise Smyle Mouth Ulcer Gel aur gynaecology ke liye Doxinate aur Clofert. Sirf Doxinate, jo morning sickness ke liye use hota hai, uski sales hi saal mein ₹110 crore ke aas paas hai! Company ka moving annual turnover February 2026 tak ₹504 crore tha, jo ki 6% growth rate dikha raha tha.
Warburg Ka Bada Plan Hai India Mein
Ye acquisition Warburg Pincus ke ek bade plan ka hissa hai. Wo India mein 2 se 3 pharma companies ko milakar ek bada business platform banana chahte hain. Iske liye wo ek experienced leader bhi dhoondh rahe hain. Aisi khabrein hain ki Merck & Co. India ke ex-head Rehan Khan ko bhi is role ke liye consider kiya ja sakta hai. Pichli baar Warburg ne ₹1,200 crore mein Integrace Health kharidne ki koshish ki thi, jisse pata chalta hai ki ye log Indian healthcare sector mein kaafi serious hain.